Physician profile
Jeffrey S Scheib
NPI 1275610370
$734.01
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $68.30 · 2021: $226 · 2022: $65.29.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $266.44 | 2019-2022 | |
| Amgen INC. | $158.64 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $83.14 | 2019-2021 | |
| Janssen Biotech, INC. | $41.10 | 2021 | |
| Pfizer INC. | $39.70 | 2019-2021 | |
| Novo Nordisk INC | $37.56 | 2021-2022 | |
| Glaxosmithkline, LLC. | $28.82 | 2020-2021 | |
| Genzyme Corporation | $17.51 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.29 | 2022 | |
| Ascend Therapeutics US, LLC | $11.82 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.81 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.70 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.48 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Scheib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.